Moores Cancer Center at the University of California San Diego has received a $1 million donation from pharmaceutical company ...

Pharma giant Pfizer and Arvinas’s human epidermal growth factor receptor 2 (HER2) negative breast cancer therapy, vepdegestrant, has seen mixed results after it was only able to extend ...

Pfizer has revealed that its much-anticipated selective oestrogen receptor degrader (SERD) vepdegestrant for breast cancer missed the mark for a key endpoint in its first phase 3 trial readout.

Arvinas' ARV-102 reduced LRRK2 protein in a Phase 1 trial, showing promising safety and pharmacodynamic outcomes for ...

March 11 (Reuters) - Pfizer (PFE.N), opens new tab and Arvinas' (ARVN.O), opens new tab experimental treatment failed to delay progression of breast cancer in patients with most common type of the ...

Healthcare stocks have been out of vogue with investors since late 2022. Myriad reasons underlie the negative sentiment ...

U.S. breast cancer deaths are no longer decreasing in women younger than 40, older than 74, or of Asian, Hispanic, or Native American descent. Experts share what they think is behind these and other ...

Vepdegestrant (ARV-471) yielded a statistically significant and clinically meaningful improvement in progression-free ...

Early toxicities associated with a 3-week hypofractionated radiotherapy regimen do not raise initial safety concerns in women ...

Pfizer and Arvinas' experimental breast cancer treatment failed to delay the progression of the disease in a broader group of patients in a late-stage trial, sending the ...